Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group

被引：0
|
作者：
Smith, J. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Buyse, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rastogi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Geyer, C., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Jacobs, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Patocskai, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wolmark, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Columbia River Oncol Program, Portland, OR USA
[2] IDDI, Louvain, Belgium
[3] NSABP, Pittsburgh, PA USA
[4] UPCI, Magee Womens Hosp, Womens Canc Clin, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[7] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A cases of pertuzumab plus trastuzumab plus docetaxel was effective for inflammatory breast cancer with HER2-positive
    Yamashita, Yuji
    Tanaka, Yuko
    Nishimura, Meiko
    Mukohara, Toru
    Kono, Seishi
    Takao, Shintaro
    Minami, Hironobu
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [22] Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results
    Michalaki, Vasiliki
    Fotiou, Stylianos
    Gennatas, Spyridon
    Gennatas, Constantine
    ANTICANCER RESEARCH, 2010, 30 (07) : 3051 - 3054
  • [23] Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC).
    Saracchini, Silvana
    Foltran, Luisa
    Bassini, Anna
    Faro, Sandro Su
    Lorenzon, Michele
    Micheli, Elvia
    Favero, Alessandro
    Marus, Wally
    Del Conte, Alessandro
    Gusso, Giuseppina
    Manente, Stefania
    Tumolo, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [25] Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial
    Tokunaga, Shinya
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Kawajiri, Hidemi
    Tokumoto, Mao
    Nishimura, Shigehiko
    Nishimori, Takeo
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Mizuyama, Yoko
    Sunami, Takeshi
    Tezuka, Kenji
    Yamagata, Shigehito
    Ishikawa, Tetsuro
    Kudoh, Shinzoh
    Takada, Minoru
    Hirakawa, Kosei
    Ohira, Masaichi
    ANTICANCER RESEARCH, 2019, 39 (04) : 2053 - 2059
  • [26] Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Zetina, L.
    Dias Gaui, M. da Fatima
    Reyes, D. Otero
    Jassem, J.
    Button, P.
    Bell, R.
    EJC SUPPLEMENTS, 2008, 6 (07): : 109 - 110
  • [27] Docetaxel, carboplatin and weekly trastuzumab are active as neoadjuvant therapy in operable HER2-positive breast cancer
    Kolberg, H. -C.
    Akpolat-Basci, L.
    Otterbach, F.
    Drumm, A.
    Tirier, C.
    BREAST, 2011, 20 : S74 - S74
  • [28] Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
    Rocca, Andrea
    Cortesi, Pietro
    Cortesi, Laura
    Gianni, Lorenzo
    Matteucci, Federica
    Fantini, Lorenzo
    Maestri, Antonio
    Giunchi, Donata Casadei
    Cavanna, Luigi
    Ciani, Rosa
    Falcini, Fabio
    Bagni, Antonella
    Meldoli, Elena
    Dall'Agata, Monia
    Volpi, Roberta
    Andreis, Daniele
    Nanni, Oriana
    Curcio, Annalisa
    Lucchi, Leonardo
    Amadori, Dino
    Fedeli, Anna
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [29] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Inoue, Kenichi
    Nakagami, Kazuhiko
    Mizutani, Mitsuhiro
    Hozumi, Yasuo
    Fujiwara, Yasuhiro
    Masuda, Norikazu
    Tsukamoto, Fumine
    Saito, Mitsue
    Miura, Shigeto
    Eguchi, Kenji
    Shinkai, Tetsu
    Ando, Masashi
    Watanabe, Toru
    Masuda, Noriyuki
    Ohashi, Yasuo
    Sano, Muneaki
    Noguchi, Shinzaburo
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 127 - 136
  • [30] Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
    Kenichi Inoue
    Kazuhiko Nakagami
    Mitsuhiro Mizutani
    Yasuo Hozumi
    Yasuhiro Fujiwara
    Norikazu Masuda
    Fumine Tsukamoto
    Mitsue Saito
    Shigeto Miura
    Kenji Eguchi
    Tetsu Shinkai
    Masashi Ando
    Toru Watanabe
    Noriyuki Masuda
    Yasuo Ohashi
    Muneaki Sano
    Shinzaburo Noguchi
    Breast Cancer Research and Treatment, 2010, 119 : 127 - 136
12345